Faculty: Ashok Malla, MD, Rahul Manchanda, MD, Philip Tibbo, MD, Richard Williams, MD, Ridha Joober, MD
Sponsor: Schizophrenia Society of Canada Foundation and Otsuka-Lundbeck Alliance
In 2013, the CCEIP created an assessment tool for the prediction of relapse in early psychosis to be used in clinical settings. A multi-site study was conducted in 2016 to assess the feasibility and reliability of the tool, now named The Scale for Early Psychosis Relapse Risk Assessment (SEPRRA).
The SEPRRA tool has been assessed for feasibility and reliability, but before it can be used in routine clinical practice, the validity must be evaluated. If your clinic is interested in participating in the validation of this important tool, please reach out to Megan Connolly at firstname.lastname@example.org for more details.
Sponsor - Janssen
A tool for patient engagement:
- This tool allows for a systematic discussion about the option of LAIs with patients
- It helps to make LAIs a choice, rather than a punishment
- Relapses worsen the long term patient trajectory
- The best way to avoid relapse is continuous antipsychotic treatment
FacultyThomas Hastings, MD, FRCPC
Associate Clinical Professor, Department of Psychiatry, McMaster University, Hamilton, Ontario
Howard C. Margolese, MD, CM, MSc, FRCPC
Associate Professor, Department of Psychiatry, McGill University, Montréal, Québec
Phil Tibbo, MD, FRCPC
Dr Paul Janssen Chair in Psychotic Disorders
Professor, Department of Psychiatry, Dalhousie University, Halifax, Nova Scotia
Project Sponsor: Janssen Inc.
- Treatment recommendations is based on the following categories:
- Practical considerations (e.g. available formulations, po/im/dissolve, dosing frequency, cost)
- Efficacy considerations (e.g. symptom control/response to treatment, comparison of medications)
- Tolerability (e.g. comparison of medications based on side effects, consideration of patient medical history, use of concomitant medications)
- Electronic format that can be used on computer and/or smart phone
- The purpose of this tool is to assist clinicians in evaluating treatment options based on individual patient factors